World Congress at ACG2017

Presidential Plenary Session 1 (Free Paper/Abstract Presentations)

5 - Effectiveness of Endoscopic Therapy in Patients With Barrett’s Esophagus (BE) With Early Cancer Is Comparable to That of BE With High-Grade Dysplasia (HGD): Results From an International, Multi-center Consortium

Monday, October 16
8:48 AM - 9:00 AM
Location: Valencia Ballroom (Level 4)



Award: 2017 Category Award (Esophagus)

Category: Esophagus       

Rajesh Krishnamoorthi, MD1, Varun Thiagarajan, MD1, Sreekar Vennelaganti, MD2, Alessandro Repici, MD3, Vani Konda, MD4, Irving Waxman, MD4, Stefan Seewald, MD5, Matthew Stier, MD6, Rehan Haidry, MD7, Daniel Buckles, MD8, Neil Gupta, MD9, Ajay Bansal, MD10, Sharad Mathur, MD8, Mojtaba Olyaee, MD10, Michael Bourke, MD11, Gary Falk, MD12, Prateek Sharma, MD2, Andrew S. Ross, MD13
1Virginia Mason Medical Center, Seattle, WA; 2Kansas City VA Medical Center, Kansas City, MO; 3Instituto Clinico Humanitas, Milan, Italy; 4University of Chicago, Chicago, IL; 5Hirsladen, Zurich, Switzerland; 6University of Chicago Medical Center, Chicago, IL; 7University College London Hospital, London, United Kingdom; 8University of Kansas, Kansas City, KS; 9Loyola University, Maywood, IL; 10University of Kansas Medical Center, Kansas City, KS; 11University of Sydney, Westmead, Australia; 12Hospital of the University of Pennsylvania, Philadelphia, PA; 13Digestive Diseases Institute, Virginia Mason Clinic, Seattle, WA
Introduction: Endoscopic therapy, the current treatment of choice for BE patients with HGD, is also a noninvasive alternative to surgery for treatment of BE with intra-mucosal cancer (IMC). There are limited data comparing the outcomes of endoscopic therapy in BE patients with IMC and HGD. We aimed to compare the rates of complete eradication of intestinal metaplasia (CE-IM), complete eradication of dysplasia (CE-D) and recurrent IM (Re-IM) between the two groups –IMC and HGD.

Methods: We reviewed all BE subjects with HGD and IMC who underwent endoscopic therapy in a multicenter prospective registry. Patients were treated with endoscopic mucosal resection if visible lesions were noted and/or mucosal ablation (RFA, cryotherapy, APC) for the flat BE. Patients who underwent at least four EGDs with endoscopic therapy were included in the study. CEIM and CED was defined as histologic absence of intestinal metaplasia (IM) and dysplasia respectively. Re-IM was defined as histologic evidence of BE (IM, dysplasia or esophageal adenocarcinoma (EAC)) after achieving CEIM. Rates of CEIM, CED and Re-IM were calculated for the two study groups – IMC and HGD. Cox proportional hazard models were used to compare the outcomes of endoscopic therapy between the two groups.

Results: 276 subjects (70 with IMC and 206 with HGD) with BE who underwent endoscopic therapy were included in the study. The median (IQR) age was 66.0 (58.0, 73.0) years. 232 (84.1%) were males. There were no differences in baseline characteristics (age, sex and BE segment length) between the IMC and HGD groups (table 1). In the IMC group, 57 (81.4%) and 62 (88.6%) subjects achieved CE-IM and CE-D respectively. In the HGD group, 173 (84.0%) and 185 (89.8%) subjects achieved CE-IM and CE-D respectively. There was no statistical difference in the proportion of subjects who achieved CE-IM (p=0.62) and CE-D (p=0.77) in the two groups. On multivariate analysis adjusting for age, sex and BE length, there was no statistical difference in the CE-IM (IMC vs HGD; HR 1.15, 95% CI 0.38 – 3.51, p= 0.81) and CE-D (IMC vs HGD; HR 1.21, 95% CI 0.31-4.66, p= 0.79) rates between the two groups. There were 25 (43.9%) Re-IM in the IMC group and 60 (34.7%) Re-IM in the HGD group (p=0.21).

Discussion: In this large well-defined cohort of BE patients, effectiveness of endoscopic therapy in IMC is comparable to that of HGD. Consideration of endoscopic therapy in BE patients with early cancer could reduce the need for invasive surgery.

Supported by Industry Grant: No


Table 1: Baseline characteristics and outcomes of endoscopic therapy in IMC and HGD




















































Baseline characteristics

Total


n = 276

IMC


n = 70

HGD


n =206
p Value
Age (IQR) yrs 66.0 (58.0,73.0) 68.0 (63.0,74.0) 65.0 (58.0,72.0) 0.064
Male 232 (84.1%) 55 (78.6%) 177 (85.9%) 0.147
BE length (Median (IQR)) cm 6.0 (3.0,10.0) 5.5 (3.0,10.0) 6.0 (3.0,10.0) 0.423
CE-IM 230 (83.3%) 57 (81.4%) 173 (84.0%) 0.621
CE- D 247 (89.5%) 62 (88.6%) 185 (89.8%) 0.771
Re-IM 85 (37.0%) 25 (43.9%) 60 (34.7%) 0.214

Citation: . EFFECTIVENESS OF ENDOSCOPIC THERAPY IN PATIENTS WITH BARRETT’S ESOPHAGUS (BE) WITH EARLY CANCER IS COMPARABLE TO THAT OF BE WITH HIGH-GRADE DYSPLASIA (HGD): RESULTS FROM AN INTERNATIONAL, MULTI-CENTER CONSORTIUM. Program No. 5. World Congress of Gastroenterology at ACG2017 Meeting Abstracts. Orlando, FL: American College of Gastroenterology.

Send Email for Rajesh Krishnamoorthi


Assets

5 - Effectiveness of Endoscopic Therapy in Patients With Barrett’s Esophagus (BE) With Early Cancer Is Comparable to That of BE With High-Grade Dysplasia (HGD): Results From an International, Multi-center Consortium



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Effectiveness of Endoscopic Therapy in Patients With Barrett’s Esophagus (BE) With Early Cancer Is Comparable to That of BE With High-Grade Dysplasia (HGD): Results From an International, Multi-center Consortium